Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer

International Journal of Molecular Medicine

Volumn 33, Issue 5, 2014, Pages 1261-1267

  Kim, S E Lim ^a   Lee, Soo Teik ^a   Trang, Kieu Thi Thu ^a   Kim, Seong Hun ^a   Kim, I N Hee ^a   Lee, Seung O K ^a   Kim, Dae Ghon ^a   Kim, Sang Wook ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Angiogenesis; Colorectal cancer; Human umbilical vein endothelial cells; Parthenolide

Indexed keywords

ANGIOGENESIS INHIBITOR; PARTHENOLIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; SESQUITERPENE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; CELL MOTION; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECTS; GENETICS; HT 29 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

CELL MOVEMENT; CELL SURVIVAL; COLORECTAL NEOPLASMS; HCT116 CELLS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SESQUITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899500279     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1669     Document Type: Article

References (49)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
2. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
4. Yi ZF, Cho SG, Zhao H, et al: A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 124: 843-852, 2009.
5. Byrne AM, Bouchier-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794, 2005. (Pubitemid 43116546)
6. Okines A, Puerto OD, Cunningham D, et al: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101: 1033-1038, 2009.
7. Hsu JY and Wakelee HA: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23: 289-304, 2009.
8. Punt CJ and Tol J: More is less - combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 6: 731-733, 2009.
9. Knight DW: Feverfew: chemistry and biological activity. Nat Prod Rep 12: 271-276, 1995.
10. Carlisi D, D'Anneo A, Angileri L, et al: Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226: 1632-1641, 2011.
11. Sohma I, Fujiwara Y, Sugita Y, et al: Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 8: 39-47, 2011.
12. Zanotto-Filho A, Braganhol E, Schröder R, et al: NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81: 412-424, 2011.
13. Zhao LJ, Xu YH and Li Y: Effect of parthenolide on proliferation and apoptosis in gastric cancer cell line SGC7901. J Dig Dis 10: 172-180, 2009.
14. Park JH, Liu L, Kim IH, Kim JH, You KR and Kim DG: Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res 65: 2804-2814, 2005. (Pubitemid 40490083)
15. Kim SL, Trang KT, Kim SH, et al: Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis. Int J Oncol 41: 1547-1553, 2012.
16. Kim SL, Kim SH, Trang KT, et al: Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 335: 479-486, 2013.
17. Reischer D, Heyfets A, Shimony S, Nordenberg J, Kashman Y and Flescher E: Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. Br J Pharmacol 150: 738-749, 2007. (Pubitemid 46440216)
18. Shibuya M: Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13: 63-69, 2006.
19. Tozer GM, Kanthou C and Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435, 2005. (Pubitemid 40791485)
20. Meyer RD and Rahimi N: Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems? Ann NY Acad Sci 995: 200-207, 2003. (Pubitemid 36706627)
21. Zunino SJ, Ducore JM and Storms DH: Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett 254: 119-127, 2007. (Pubitemid 47058812)
22. Gopal YN, Chanchorn E and Van Dyke MW: Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 8: 552-562, 2009.
23. Wen J, You KR, Lee SY, Song CH and Kim DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277: 38954-38964, 2002. (Pubitemid 35154761)
24. Zhang S, Ong CN and Shen HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208: 143-153, 2004. (Pubitemid 38624155)
25. Zhang S, Ong CN and Shen HM: Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett 211: 175-188, 2004. (Pubitemid 38824631)
26. Tacchini L, De Ponti C, Matteucci E, Follis R and Desiderio MA: Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25: 2089-2100, 2004. (Pubitemid 39534845)
27. Dai Y, Guzman ML, Chen S, et al: The NF (nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151: 70-83, 2010.
28. Nakshatri H, Rice SE and Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344, 2004. (Pubitemid 39382136)
29. Wu C, Chen F, Rushing JW, et al: Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food 9: 55-61, 2006. (Pubitemid 44153618)
30. Oka D, Nishimura K, Shiba M, et al: Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer 120: 2576-2581, 2007. (Pubitemid 46651277)
31. Weng SX, Sui MH, Chen S, et al: Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest. J Zhejiang Univ Sci B 10: 528-535, 2009.
32. Kong F, Chen Z, Li Q, et al: Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism. J Huazhong Univ Sci Technolog Med Sci 28: 525-530, 2008.
33. Li CJ, Guo SF and Shi TM: Culture supernatants of breast cancer cell line MDA-MB-231 treated with parthenolide inhibit the proliferation, migration, and lumen formation capacity of human umbilical vein endothelial cells. Chin Med J (Engl) 125: 2195-2199, 2012.
34. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
35. Shibuya M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67: 281-316, 1995.
36. Shibuya M: Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol Chem 383: 1573-1579, 2002.
37. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ and Kerbel RS: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104: 17069-17074, 2007. (Pubitemid 350210993)
38. Cao Y: Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2: re1, 2009.
39. Shibuya M, Yamaguchi S, Yamane A, et al: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524, 1990.
40. Sawano A, Takahashi T, Yamaguchi S, Aonuma M and Shibuya M: Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7: 213-221, 1996. (Pubitemid 26049830)
41. Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993. (Pubitemid 23347111)
42. Plate KH, Breier G, Weich HA, Mennel HD and Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994. (Pubitemid 24357278)
43. Kaplan RN, Riba RD, Zacharoulis S, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005. (Pubitemid 41753060)
44. Murakami M, Iwai S, Hiratsuka S, et al: Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 108: 1849-1856, 2006. (Pubitemid 44394993)
45. Muramatsu M, Yamamoto S, Osawa T and Shibuya M: Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res 70: 8211-8221, 2010.
46. Kerber M, Reiss Y, Wickersheim A, et al: Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68: 7342-7351, 2008.
47. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273: 114-127, 2013.
48. Shibuya M: Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153: 13-19, 2013.
49. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005. (Pubitemid 46202320)